{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T07:06:16Z","timestamp":1777446376795,"version":"3.51.4"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2020,3,9]],"date-time":"2020-03-09T00:00:00Z","timestamp":1583712000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,3,9]],"date-time":"2020-03-09T00:00:00Z","timestamp":1583712000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Toxicol"],"published-print":{"date-parts":[[2020,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>We assessed the effects of antiandrogen therapy on ECG parameters of ventricular repolarization related to arrhythmic risk in 35 patients aged 70.3\u2009\u00b1\u20097\u00a0years with advanced prostate cancer treated with degarelix associated with enzalutamide (group A, 26 patients) or degarelix monotherapy (group B, 9 patients). We analyzed Fridericia corrected Q-T interval (QTc), Q-T dispersion (QTd), J-Tpeak interval (JTp), mean and maximum Tpeak-Tend interval (Tpe) and Tpe\/QT ratio, Tpeak-Tend dispersion (Tped), index of cardio-electrophysiological balance (iCEB) from ECG tracings, and occurrence of ventricular premature beats (VPB) recorded by Holter ECG, before initiation of medication (M0) and after 6\u00a0months of treatment (M1). The groups had similar demographics except for a higher prevalence of prior myocardial infarction in group B (<jats:italic>p<\/jats:italic>\u2009=\u20090.01). All patients had low serum testosterone at M1. Baseline QTc, QTd, maxTpe\/QT, meanTpe, maxTpe, Tped values were higher in B compared to A. They had a significant prolongation at M1 only in A. 20 patients in A and 6 in B had a 10% prolongation or decrease of iCEB (<jats:italic>p<\/jats:italic>\u2009=\u20090.66). In 5 patients, VPB severity increased from non-complex to complex: 3 in A and 2 in B (<jats:italic>p<\/jats:italic>\u2009=\u20090.31), but no sustained ventricular arrhythmia was registered. In conclusion, after 6\u00a0months of treatment, patients with hypogonadism on degarelix associated with enzalutamide had significant prolongation of QTc, QTd, maxTpe, meanTpe\/QT, maxTpe\/QT, Tped compared to patients on degarelix alone. The proportion of patients with 10% iCEB variation was similar between groups. There was no record of severe arrhythmias during the first 6\u00a0months of treatment.<\/jats:p>","DOI":"10.1007\/s12012-020-09566-6","type":"journal-article","created":{"date-parts":[[2020,3,9]],"date-time":"2020-03-09T15:02:43Z","timestamp":1583766163000},"page":"390-400","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Evolution of Electrocardiographic Repolarization Parameters During Antiandrogen Therapy in Patients with Prostate Cancer and Hypogonadism"],"prefix":"10.1007","volume":"20","author":[{"given":"Andrei Cristian Dan","family":"Gheorghe","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Ciobanu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreea Simona","family":"Hodorogea","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George Daniel","family":"Radavoi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Viorel","family":"Jinga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ioan Tiberiu","family":"Nanea","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriela Silvia","family":"Gheorghe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,3,9]]},"reference":[{"issue":"36","key":"9566_CR1","doi-asserted-by":"publisher","first-page":"2768","DOI":"10.1093\/eurheartj\/ehw211","volume":"37","author":"JL Zamorano","year":"2016","unstructured":"Zamorano, J. L., Lancellotti, P., Rodriguez Mu\u00f1oz, D., et al. (2016). ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines. European Heart Journal,37(36), 2768\u20132801. https:\/\/doi.org\/10.1093\/eurheartj\/ehw211.","journal-title":"European Heart Journal"},{"issue":"30","key":"9566_CR2","doi-asserted-by":"publisher","first-page":"3436","DOI":"10.1200\/JCO.2013.54.8404","volume":"32","author":"E Basch","year":"2014","unstructured":"Basch, E., Loblaw, D. A., Oliver, T. K., et al. (2014). Systemic therapy in men with metastatic castration-resistant prostate cancer: American society of clinical oncology and cancer care ontario clinical practice guideline. Journal of Clinical Oncology,32(30), 3436\u20133448. https:\/\/doi.org\/10.1200\/JCO.2013.54.8404.","journal-title":"Journal of Clinical Oncology"},{"key":"9566_CR3","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.pharmthera.2016.07.005","volume":"167","author":"JE Salem","year":"2016","unstructured":"Salem, J. E., Alexandre, J., Bachelot, A., & Funck-Brentano, C. (2016). Influence of steroid hormones on ventricular repolarization. Pharmacology & Therapeutics,167, 38\u201347. https:\/\/doi.org\/10.1016\/j.pharmthera.2016.07.005.","journal-title":"Pharmacology & Therapeutics"},{"issue":"1","key":"9566_CR4","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.pharmthera.2010.04.002","volume":"127","author":"MKB Jonsson","year":"2010","unstructured":"Jonsson, M. K. B., Vos, M. A., Duker, G., Demolombe, S., & van Veen, T. A. B. (2010). Gender disparity in cardiac electrophysiology: Implications for cardiac safety pharmacology. Pharmacology & Therapeutics,127(1), 9\u201318. https:\/\/doi.org\/10.1016\/j.pharmthera.2010.04.002.","journal-title":"Pharmacology & Therapeutics"},{"issue":"1","key":"9566_CR5","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1161\/CIRCULATIONAHA.118.034282","volume":"138","author":"JE Salem","year":"2018","unstructured":"Salem, J. E., Waintraub, X., Courtillot, C., et al. (2018). Hypogonadism as a reversible cause of torsades de pointes in men. Circulation,138(1), 110\u2013113. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.118.034282.","journal-title":"Circulation"},{"issue":"12","key":"9566_CR6","doi-asserted-by":"publisher","first-page":"717","DOI":"10.11909\/j.issn.1671-5411.2017.12.001","volume":"14","author":"A Ciobanu","year":"2017","unstructured":"Ciobanu, A., Tse, G., Liu, T., et al. (2017). Electrocardiographic measures of repolarization dispersion and their relationships with echocardiographic indices of ventricular remodeling and premature ventricular beats in hypertension. Journal of Geriatric Cardiology,14(12), 717\u2013724. https:\/\/doi.org\/10.11909\/j.issn.1671-5411.2017.12.001.","journal-title":"Journal of Geriatric Cardiology"},{"issue":"5","key":"9566_CR7","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1093\/europace\/euw280","volume":"19","author":"G Tse","year":"2017","unstructured":"Tse, G., & Yan, B. P. (2017). Traditional and novel electrocardiographic conduction and repolarization markers of sudden cardiac death. EP Eurospace,19(5), 712\u2013721. https:\/\/doi.org\/10.1093\/europace\/euw280.","journal-title":"EP Eurospace"},{"issue":"8","key":"9566_CR8","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1016\/j.hrthm.2017.05.031","volume":"14","author":"G Tse","year":"2017","unstructured":"Tse, G., Gong, M., Wong, W. T., et al. (2017). The Tpeak\u2212Tend interval as an electrocardiographic risk marker of arrhythmic and mortality outcomes: A systematic review and meta-analysis. Heart Rhythm,14(8), 1131\u20131137. https:\/\/doi.org\/10.1016\/j.hrthm.2017.05.031.","journal-title":"Heart Rhythm"},{"issue":"3","key":"9566_CR9","doi-asserted-by":"publisher","first-page":"223","DOI":"10.28982\/josam.485247","volume":"3","author":"Y Alsancak","year":"2019","unstructured":"Alsancak, Y., G\u00fcrb\u00fcz, A. S., Sakl\u0131, B., & \u0130\u00e7li, A. (2019). Evaluation of index of cardio-electrophysiological balance and Tp-e\/QT ratio in patients with coronary artery ectasia. Journal of Surgery and Medicine,3(3), 223\u2013226. https:\/\/doi.org\/10.28982\/josam.485247.","journal-title":"Journal of Surgery and Medicine"},{"issue":"6","key":"9566_CR10","doi-asserted-by":"publisher","first-page":"3264","DOI":"10.1161\/JAHA.116.003264","volume":"5","author":"B Vandenberk","year":"2016","unstructured":"Vandenberk, B., Vandael, E., Robyns, T., et al. (2016). Which QT Correction Formulae to Use for QT Monitoring? Journal of the American Heart Association,5(6), 3264. https:\/\/doi.org\/10.1161\/JAHA.116.003264.","journal-title":"Journal of the American Heart Association"},{"key":"9566_CR11","unstructured":"National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE).v.5.0. Cancer Therapy Evaluation Program 2017:183."},{"key":"9566_CR12","unstructured":"Gheorghe ACD, Ciobanu A, Hodorogea AS, et al. Electrocardiographic parameters of repolarization and heart rate variability in prostate cancer patients with drug induced hypogonadism. Mendeley Data 2020;3. doi:10.17632\/YJSP52K9SC.3"},{"issue":"21","key":"9566_CR13","doi-asserted-by":"publisher","first-page":"3452","DOI":"10.1200\/JCO.2008.20.0923","volume":"27","author":"SMH Alibhai","year":"2009","unstructured":"Alibhai, S. M. H., Duong-Hua, M., Sutradhar, R., et al. (2009). Impact of androgen deprivation therapy on cardiovascular disease and diabetes. Journal of Clinical Oncology,27(21), 3452\u20133458. https:\/\/doi.org\/10.1200\/JCO.2008.20.0923.","journal-title":"Journal of Clinical Oncology"},{"issue":"20","key":"9566_CR14","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.1093\/jnci\/djm168","volume":"99","author":"HK Tsai","year":"2007","unstructured":"Tsai, H. K., D\u2019Amico, A. V., Sadetsky, N., Chen, M. H., & Carroll, P. R. (2007). Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality. Journal of the National Cancer Instititue,99(20), 1516\u20131524. https:\/\/doi.org\/10.1093\/jnci\/djm168.","journal-title":"Journal of the National Cancer Instititue"},{"issue":"11","key":"9566_CR15","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1200\/JCO.2014.60.2649","volume":"33","author":"S Basaria","year":"2015","unstructured":"Basaria, S. (2015). Cardiovascular disease associated with androgen-deprivation therapy: Time to give it due respect. Journal of Clinical Oncology,33(11), 1232\u20131234. https:\/\/doi.org\/10.1200\/JCO.2014.60.2649.","journal-title":"Journal of Clinical Oncology"},{"issue":"26","key":"9566_CR16","doi-asserted-by":"publisher","first-page":"3510","DOI":"10.1200\/JCO.2011.35.1494","volume":"29","author":"S Punnen","year":"2011","unstructured":"Punnen, S., Cooperberg, M. R., Sadetsky, N., & Carroll, P. R. (2011). Androgen deprivation therapy and cardiovascular risk. Journal of Clinical Oncology,29(26), 3510\u20133516. https:\/\/doi.org\/10.1200\/JCO.2011.35.1494.","journal-title":"Journal of Clinical Oncology"},{"key":"9566_CR17","doi-asserted-by":"publisher","first-page":"129","DOI":"10.2147\/DHPS.S50549","volume":"7","author":"JF Lester","year":"2015","unstructured":"Lester, J. F., & Mason, M. D. (2015). Cardiovascular effects of hormone therapy for prostate cancer. Drug, Healthcare and Patient Safety,7, 129\u2013138. https:\/\/doi.org\/10.2147\/DHPS.S50549.","journal-title":"Drug, Healthcare and Patient Safety"},{"issue":"27","key":"9566_CR18","doi-asserted-by":"publisher","first-page":"4448","DOI":"10.1200\/JCO.2006.06.2497","volume":"24","author":"NL Keating","year":"2006","unstructured":"Keating, N. L., O\u2019Malley, A. J., & Smith, M. R. (2006). Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. Journal of Clinical Oncology,24(27), 4448\u20134456. https:\/\/doi.org\/10.1200\/JCO.2006.06.2497.","journal-title":"Journal of Clinical Oncology"},{"key":"9566_CR19","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1161\/CIRCULATIONAHA.104.523217","volume":"112","author":"C Bai","year":"2005","unstructured":"Bai, C., Kurokawa, J., Tamagawa, M., Nakaya, H., & Furukawa, T. (2005). Nontranscriptional regulation of cardiac repolarization currents by testosterone. Circulation,112, 1701.","journal-title":"Circulation"},{"issue":"1","key":"9566_CR20","doi-asserted-by":"publisher","first-page":"e132","DOI":"10.1111\/j.1365-2605.2009.00985.x","volume":"33","author":"F Pecori Giraldi","year":"2010","unstructured":"Pecori Giraldi, F., Toja, P. M., Filippini, B., et al. (2010). Increased prevalence of prolonged QT interval in males with primary or secondary hypogonadism: A pilot study. Internationl Journal of Andrology,33(1), e132\u2013e138. https:\/\/doi.org\/10.1111\/j.1365-2605.2009.00985.x.","journal-title":"Internationl Journal of Andrology"},{"issue":"4","key":"9566_CR21","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1093\/aje\/kwr172","volume":"174","author":"Y Zhang","year":"2011","unstructured":"Zhang, Y., Ouyang, P., Post, W. S., et al. (2011). Sex-steroid hormones and electrocardiographic qt-interval duration: Findings from the third national health and nutrition examination survey and the multi-ethnic study of atherosclerosis. American Journal of Epidemiology,174(4), 403\u2013411. https:\/\/doi.org\/10.1093\/aje\/kwr172.","journal-title":"American Journal of Epidemiology"},{"issue":"6","key":"9566_CR22","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1016\/j.amjcard.2008.11.041","volume":"103","author":"B Charbit","year":"2009","unstructured":"Charbit, B., Christin-Ma\u00eetre, S., D\u00e9molis, J. L., Soustre, E., Young, J., & Funck-Brentano, C. (2009). Effects of testosterone on ventricular repolarization in hypogonadic men. American Journal of Cardiology,103(6), 887\u2013890. https:\/\/doi.org\/10.1016\/j.amjcard.2008.11.041.","journal-title":"American Journal of Cardiology"},{"issue":"9","key":"9566_CR23","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1089\/jwh.2011.3444","volume":"21","author":"T Sedlak","year":"2012","unstructured":"Sedlak, T., Shufelt, C., Iribarren, C., & Merz, C. N. B. (2012). Sex hormones and the QT interval: A review. Journal of Women\u2019s Health,21(9), 933\u2013941. https:\/\/doi.org\/10.1089\/jwh.2011.3444.","journal-title":"Journal of Women\u2019s Health"},{"issue":"5","key":"9566_CR24","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1093\/cvr\/cvz020","volume":"115","author":"M Barber","year":"2019","unstructured":"Barber, M., Nguyen, L. S., Wassermann, J., Spano, J. P., Funck-Brentano, C., & Salem, J. E. (2019). Cardiac arrhythmia considerations of hormone cancer therapies. Cardiovascular Research,115(5), 878\u2013894. https:\/\/doi.org\/10.1093\/cvr\/cvz020.","journal-title":"Cardiovascular Research"},{"issue":"5","key":"9566_CR25","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1177\/2042098612454283","volume":"3","author":"S Nachimuthu","year":"2012","unstructured":"Nachimuthu, S., Assar, M. D., & Schussler, J. M. (2012). Drug-induced QT interval prolongation: Mechanisms and clinical management. Therapeutic Advances in Drug Safety,3(5), 241\u2013253. https:\/\/doi.org\/10.1177\/2042098612454283.","journal-title":"Therapeutic Advances in Drug Safety"},{"issue":"5","key":"9566_CR26","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1021\/tx800035b","volume":"21","author":"JS Mitcheson","year":"2008","unstructured":"Mitcheson, J. S. (2008). hERG potassium channels and the structural basis of drug-induced arrhythmias. Chemical Research in Toxicology,21(5), 1005\u20131010. https:\/\/doi.org\/10.1021\/tx800035b.","journal-title":"Chemical Research in Toxicology"},{"issue":"1","key":"9566_CR27","doi-asserted-by":"publisher","first-page":"14698","DOI":"10.1038\/s41598-017-14413-w","volume":"7","author":"N Melong","year":"2017","unstructured":"Melong, N., Steele, S., MacDonald, M., et al. (2017). Enzalutamide inhibits testosterone-induced growth of human prostate cancer xenografts in zebrafish and can induce bradycardia. Scientific Reports,7(1), 14698. https:\/\/doi.org\/10.1038\/s41598-017-14413-w.","journal-title":"Scientific Reports"},{"key":"9566_CR28","doi-asserted-by":"crossref","unstructured":"O\u2019Farrell S, Garmo H, Holmberg L, Adolfsson J, Stattin P, Van Hemelrijck M. Risk and timing of cardiovascular disease after androgen-deprivation therapy in men with prostate cancer. In: Journal of Clinical Oncology: American Society of Clinical Oncology; 2015;33:1243\u20131251. doi:10.1200\/JCO.2014.59.1792","DOI":"10.1200\/JCO.2014.59.1792"},{"issue":"3","key":"9566_CR29","doi-asserted-by":"publisher","first-page":"e645","DOI":"10.1016\/j.clgc.2017.12.007","volume":"16","author":"R Iacovelli","year":"2018","unstructured":"Iacovelli, R., Ciccarese, C., Bria, E., et al. (2018). The cardiovascular toxicity of abiraterone and enzalutamide in prostate cancer. Clin Genitourin Cancer.,16(3), e645\u2013e653. https:\/\/doi.org\/10.1016\/j.clgc.2017.12.007.","journal-title":"Clin Genitourin Cancer."},{"issue":"13","key":"9566_CR30","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1161\/CIRCULATIONAHA.119.040162","volume":"140","author":"JE Salem","year":"2019","unstructured":"Salem, J. E., Yang, T., Moslehi, J. J., et al. (2019). Androgenic effects on ventricular repolarization: A translational study from the international pharmacovigilance database to iPSC-cardiomyocytes. Circulation,140(13), 1070\u20131080. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.119.040162.","journal-title":"Circulation"},{"issue":"26","key":"9566_CR31","doi-asserted-by":"publisher","first-page":"2465","DOI":"10.1056\/NEJMoa1800536","volume":"378","author":"M Hussain","year":"2018","unstructured":"Hussain, M., Fizazi, K., Saad, F., et al. (2018). Enzalutamide in men with nonmetastatic, castration-resistant prostate cancer. The New England Journal of Medicine,378(26), 2465\u20132474. https:\/\/doi.org\/10.1056\/NEJMoa1800536.","journal-title":"The New England Journal of Medicine"},{"issue":"11","key":"9566_CR32","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/j.acvd.2019.06.008","volume":"112","author":"JE Salem","year":"2019","unstructured":"Salem, J. E., Bretagne, M., Lebrun-Vignes, B., et al. (2019). Clinical characterization of men with long QT syndrome and torsades de pointes associated with hypogonadism: A review and pharmacovigilance study. Archives of Cardiovascular Diseases,112(11), 699\u2013712. https:\/\/doi.org\/10.1016\/j.acvd.2019.06.008.","journal-title":"Archives of Cardiovascular Diseases"},{"issue":"5","key":"9566_CR33","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1210\/js.2018-00039","volume":"2","author":"T Gagliano-Juc\u00e1","year":"2018","unstructured":"Gagliano-Juc\u00e1, T., Travison, T. G., Kantoff, P. W., et al. (2018). Androgen deprivation therapy is associated with prolongation of QTc interval in men with prostate cancer. Journal of Endocrine Society,2(5), 485\u2013496. https:\/\/doi.org\/10.1210\/js.2018-00039.","journal-title":"Journal of Endocrine Society"},{"issue":"2","key":"9566_CR34","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.vascn.2013.01.003","volume":"68","author":"HR Lu","year":"2013","unstructured":"Lu, H. R., Yan, G.-X., & Gallacher, D. J. (2013). A new biomarker \u2013 index of Cardiac Electrophysiological Balance (iCEB) \u2013 plays an important role in drug-induced cardiac arrhythmias: Beyond QT-prolongation and Torsades de Pointes (TdPs). Journal of Pharmacological and Toxicological Methods.,68(2), 250\u2013259. https:\/\/doi.org\/10.1016\/j.vascn.2013.01.003.","journal-title":"Journal of Pharmacological and Toxicological Methods."},{"issue":"9","key":"9566_CR35","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1007\/s40618-019-01026-5","volume":"42","author":"G Piccirillo","year":"2019","unstructured":"Piccirillo, G., Moscucci, F., Pofi, R., et al. (2019). Changes in left ventricular repolarization after short-term testosterone replacement therapy in hypogonadal males. Journal of Endocrinological Investigation,42(9), 1051\u20131065. https:\/\/doi.org\/10.1007\/s40618-019-01026-5.","journal-title":"Journal of Endocrinological Investigation"}],"container-title":["Cardiovascular Toxicology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12012-020-09566-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12012-020-09566-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12012-020-09566-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,9]],"date-time":"2021-03-09T01:19:32Z","timestamp":1615252772000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12012-020-09566-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,9]]},"references-count":35,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["9566"],"URL":"https:\/\/doi.org\/10.1007\/s12012-020-09566-6","relation":{},"ISSN":["1530-7905","1559-0259"],"issn-type":[{"value":"1530-7905","type":"print"},{"value":"1559-0259","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,9]]},"assertion":[{"value":"9 March 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in this study involving human participants were in accordance with the ethical standards of the institutional research committee (Theodor Burghele Clinical Hospital Ethics Committee, reference number 2\/01.2017) and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"This article does not contain any studies with animals performed by any of the authors.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed Consent"}}]}}